KOD Key Statistics, Chart & Performance
The current stock price of KOD is 26.02 USD. In the past month the price increased by 13.33%. In the past year, price increased by 185.31%.
KOD Latest News, Press Relases and Analysis
KOD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About KOD
Company Profile
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 123 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Company Info
KODIAK SCIENCES INC
1250 Page Mill Rd
Palo Alto CALIFORNIA 94304 US
CEO: Victor Perlroth
Employees: 123
Phone: 16502810850
KODIAK SCIENCES INC / KOD FAQ
What does KODIAK SCIENCES INC do?
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 123 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
What is the stock price of KODIAK SCIENCES INC today?
The current stock price of KOD is 26.02 USD. The price decreased by -6.94% in the last trading session.
Does KOD stock pay dividends?
KOD does not pay a dividend.
How is the ChartMill rating for KODIAK SCIENCES INC?
KOD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for KODIAK SCIENCES INC?
KODIAK SCIENCES INC (KOD) operates in the Health Care sector and the Biotechnology industry.
Can you provide the short interest for KOD stock?
The outstanding short interest for KODIAK SCIENCES INC (KOD) is 9.44% of its float.
KOD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KOD. When comparing the yearly performance of all stocks, KOD is one of the better performing stocks in the market, outperforming 98.61% of all stocks.
KOD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KOD. The financial health of KOD is average, but there are quite some concerns on its profitability.
KOD Financial Highlights
Over the last trailing twelve months KOD reported a non-GAAP Earnings per Share(EPS) of -4.12. The EPS decreased by -12.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.66% | ||
| ROE | -917.34% | ||
| Debt/Equity | 0 |
KOD Forecast & Estimates
12 analysts have analysed KOD and the average price target is 22.59 USD. This implies a price decrease of -13.2% is expected in the next year compared to the current price of 26.02.